CF PharmTech (02652) reported that on 05 February 2026, a total of 11,000 H shares were repurchased on the Stock Exchange at prices ranging from HKD 34.7 to HKD 35.24, with an aggregate amount of HKD 385,280. These repurchased shares are held as treasury shares, increasing the total treasury shares to 212,000.

Following this transaction, the number of issued shares (excluding treasury shares) stands at 302,011,586, while the total number of issued shares remains at 302,223,586. The repurchase was carried out under a mandate resolved on 16 December 2025, which authorized up to 30,222,358 shares for repurchase. So far, 212,000 shares have been repurchased, representing approximately 0.0701% of the issued shares as of the resolution date.

According to the announcement, there is a 30-day period during which no new issuance or sale or transfer of treasury shares is permitted, lasting until 07 March 2026, unless approval is obtained from the Stock Exchange.